Emanual Maverakis
University of California, Davis · UC Davis
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Emanual Maverakis as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:48 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05040204 · The Effects of Dietary Supplementation on Serum Protein GlycosylationUniversity of California, Davis · recruiting · Healthy · principal investigator
- Ph1NCT04466761 · Ascending Glycan Dietary Supplementation in Healthy AdultsUniversity of California, Davis · terminated · Healthy Individuals · principal investigator
- Ph3NCT04128176 · Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous PemphigoidUniversity of California, Davis · withdrawn · Bullous Pemphigoid · principal investigator
- Ph1NCT03437005 · Alternation in the Human Microbiome With Commonly Used Topical MedicationsUniversity of California, Davis · recruiting · Healthy · principal investigator
- Ph1/Ph2NCT02319616 · Topical Clobetasol for the Treatment of Toxic Epidermal NecrolysisUniversity of California, Davis · withdrawn · Toxic Epidermal Necrolysis · principal investigator
- Ph1NCT02286999 · Probiotic Supplementation in Breastfed Newborn InfantsEmanual Maverakis, MD · withdrawn · Atopic Dermatitis, Food Allergies · principal investigator
- N/ANCT00368615 · Characterization of the Melanoma-Specific Immune ResponseUniversity of California, Davis · unknown · Melanoma · principal investigator
- N/ANCT00368784 · T Cell Repertoire Analysis of Immune Mediated Skin DiseasesUniversity of California, Davis · completed · Psoriasis, Mycosis Fungoides · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Immune Modeling, Analysis, and Diagnostics Shared ResourceP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2026 · $158,874 awarded in 2026Same name and institution; not confirmed by an ID
- HIV Reservoir and Gene Modified Cell Dynamics Following Autologous Stem Cell TransplantationR01AI176951 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2023 to 2025 · $781,939 awarded in 2025Same name and institution; not confirmed by an ID
- Mentoring Translational Scientists in Clinical Trial Immune MonitoringK24AR077313 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2021 to 2025 · $187,710 awarded in 2025Grant number is on one of their registry trials
- Stratedigm S100EON high-parameter flow cytometer to support multi-institutional research programsS10OD032406 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2022 · $599,752 awarded in 2022Same name and institution; not confirmed by an ID
- Investigation and Development of New Therapeutic Avenues for SclerodermaDP2OD008752 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2011 to 2016 · $510,250 awarded in 2016Same name and institution; not confirmed by an ID
- Characterization of Pathogenic T cells in Alopecia AreataR03AR059312 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2010 to 2012 · $73,800 awarded in 2012Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:48 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).J Am Acad Dermatol · 2021117 citationsRCR 8.3
- Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.N Engl J Med · 2021105 citationsRCR 7.5
- Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial.JAMA Netw Open · 201872 citationsRCR 4.4
- Patient-centered, direct-access online care for management of atopic dermatitis: a randomized clinical trial.JAMA Dermatol · 201565 citationsRCR 3.4
- A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.Clin Cancer Res · 201940 citationsRCR 1.2
- Online Care Versus In-Person Care for Improving Quality of Life in Psoriasis: A Randomized Controlled Equivalency Trial.J Invest Dermatol · 201934 citationsRCR 2.4
- Safety of light emitting diode-red light on human skin: Two randomized controlled trials.J Biophotonics · 202032 citationsRCR 3.1
- Access to Dermatological Care with an Innovative Online Model for Psoriasis Management: Results from a Randomized Controlled Trial.Telemed J E Health · 201925 citationsRCR 2.1
- Disruption of latent HIV in vivo during the clearance of actinic keratosis by ingenol mebutate.JCI Insight · 201925 citationsRCR 1.0
- 21 citationsRCR 1.2